FLC Capital Advisors’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $1.53M | Buy |
6,063
+801
| +15% | +$172K | 0.25% | 68 |
|
|
2026
Q1 | $1.14M | Sell |
5,262
-115
| -2% | -$25.5K | 0.2% | 71 |
|
|
2025
Q4 | $1.23M | Sell |
5,377
-241
| -4% | -$54.9K | 0.23% | 67 |
|
|
2025
Q3 | $1.3M | Buy |
5,618
+5
| +0.1% | +$1.02K | 0.25% | 58 |
|
|
2025
Q2 | $1.04M | Buy |
5,613
+424
| +8% | +$78.8K | 0.22% | 65 |
|
|
2025
Q1 | $1.09M | Buy |
5,189
+282
| +6% | +$54.8K | 0.24% | 59 |
|
|
2024
Q4 | $872K | Buy |
4,907
+135
| +3% | +$24.8K | 0.2% | 71 |
|
|
2024
Q3 | $942K | Sell |
4,772
-945
| -17% | -$176K | 0.22% | 64 |
|
|
2024
Q2 | $981K | Sell |
5,717
-1,040
| -15% | -$172K | 0.24% | 57 |
|
|
2024
Q1 | $1.23M | Sell |
6,757
-135
| -2% | -$23.3K | 0.31% | 49 |
|
|
2023
Q4 | $1.07M | Sell |
6,892
-60
| -0.9% | -$8.75K | 0.29% | 54 |
|
|
2023
Q3 | $1.04M | Sell |
6,952
-80
| -1% | -$11.7K | 0.31% | 53 |
|
|
2023
Q2 | $947K | Sell |
7,032
-1,000
| -12% | -$147K | 0.28% | 56 |
|
|
2023
Q1 | $1.28M | Sell |
8,032
-2,294
| -22% | -$351K | 0.39% | 54 |
|
|
2022
Q4 | $1.67M | Sell |
10,326
-650
| -6% | -$99.7K | 0.52% | 44 |
|
|
2022
Q3 | $1.47M | Sell |
10,976
-1,465
| -12% | -$210K | 0.51% | 48 |
|
|
2022
Q2 | $1.91M | Hold |
12,441
| – | – | 0.64% | 44 |
|
|
2022
Q1 | $2.02M | Sell |
12,441
-350
| -3% | -$50.8K | 0.57% | 47 |
|
|
2021
Q4 | $1.73M | Sell |
12,791
-618
| -5% | -$73K | 0.48% | 59 |
|
|
2021
Q3 | $1.45M | Hold |
13,409
| – | – | 0.43% | 60 |
|
|
2021
Q2 | $1.51M | Buy |
13,409
+80
| +0.6% | +$9.01K | 0.44% | 61 |
|
|
2021
Q1 | $1.44M | Buy |
13,329
+100
| +0.8% | +$10.7K | 0.45% | 61 |
|
|
2020
Q4 | $1.42M | Buy |
13,229
+859
| +7% | +$82.5K | 0.47% | 56 |
|
|
2020
Q3 | $1.04M | Buy |
12,370
+1,451
| +13% | +$137K | 0.38% | 60 |
|
|
2020
Q2 | $1.08M | Buy |
10,919
+1,513
| +16% | +$133K | 0.43% | 53 |
|
|
2020
Q1 | $707K | Buy |
9,406
+3,680
| +64% | +$313K | 0.33% | 49 |
|
|
2019
Q4 | $507K | Sell |
5,726
-261
| -4% | -$21.7K | 0.2% | 60 |
|
|
2019
Q3 | $453K | Sell |
5,987
-724
| -11% | -$49.6K | 0.19% | 64 |
|
|
2019
Q2 | $478K | Buy |
6,711
+989
| +17% | +$77.7K | 0.2% | 66 |
|
|
2019
Q1 | $461K | Buy |
5,722
+776
| +16% | +$63.5K | 0.21% | 58 |
|
|
2018
Q4 | $456K | Buy |
+4,946
| New | +$435K | 0.31% | 51 |
|
Other funds holding ABBV
FLC Capital Advisors's ABBV Position: Q2 2026 in Review
FLC Capital Advisors increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $172K and bringing the position to 6,063 shares worth $1.53M. The position accounts for 0.25% of the portfolio, ranked #68.
FLC Capital Advisors first reported a position in ABBV in Q4 2018 and has held it in 31 quarters since. The position peaked at $2.02M in Q1 2022. 4,201 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- FLC Capital Advisors held 6,063 shares of AbbVie worth $1.53M as of Q2 2026.
- FLC Capital Advisors bought 801 AbbVie shares in Q2 2026, an estimated $172K.
- AbbVie made up 0.25% of FLC Capital Advisors's portfolio in Q2 2026, its #68 holding.
- FLC Capital Advisors first reported a position in AbbVie in Q4 2018 and has held it in 31 quarters since.
- FLC Capital Advisors's AbbVie position peaked at $2.02M in Q1 2022.
- 4,201 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on FLC Capital Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.